Abstract
Though prostate cancer is often indolent, it is nonetheless a leading cause of cancer death. Defining the underlying molecular genetic alterations may lead to new strategies for prevention or treatment. Towards this goal, we performed array-based comparative genomic hybridization (CGH) on 86 primary prostate tumors. Among the most frequent alterations not associated with a known cancer gene, we identified focal deletions within 5q21 in 15 out of 86 (17%) cases. By high-resolution tiling array CGH, the smallest common deletion targeted just one gene, the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1). Expression of CHD1 was significantly reduced in tumors with deletion (P=0.03), and compared with normal prostate (P=0.04). Exon sequencing analysis also uncovered nonsynonymous mutations in 1 out of 7 (14%) cell lines (LAPC4) and in 1 out of 24 (4%) prostate tumors surveyed. RNA interference-mediated knockdown of CHD1 in two nontumorigenic prostate epithelial cell lines, OPCN2 and RWPE-1, did not alter cell growth, but promoted cell invasiveness, and in OPCN2-enhanced cell clonogenicity. Taken together, our findings suggest that CHD1 deletion may underlie cell invasiveness in a subset of prostate cancers, and indicate a possible novel role of altered chromatin remodeling in prostate tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bagchi A, Mills AA . (2008). The quest for the 1p36 tumor suppressor. Cancer Res 68: 2551–2556.
Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D et al. (2007). CHD5 is a tumor suppressor at human 1p36. Cell 128: 459–475.
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY et al. (2011). The genomic complexity of primary human prostate cancer. Nature 470: 214–220.
Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D et al. (2007). Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 104: 20007–20012.
Binkley J, Karra K, Kirby A, Hosobuchi M, Stone EA, Sidow A . (2010). ProPhylER: a curated online resource for protein function and structure based on evolutionary constraint analyses. Genome Res 20: 142–154.
Damber JE, Aus G . (2008). Prostate cancer. Lancet 371: 1710–1721.
DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI . (2003). Pathological and molecular aspects of prostate cancer. Lancet 361: 955–964.
Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C et al. (2010). COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38: D652–D657.
Gaspar-Maia A, Alajem A, Polesso F, Sridharan R, Mason MJ, Heidersbach A et al. (2009). Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 460: 863–868.
Hall JA, Georgel PT . (2007). CHD proteins: a diverse family with strong ties. Biochem Cell Biol 85: 463–476.
Jemal A, Siegel R, Xu J, Ward E . (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R et al. (2010). Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228–231.
Kessenbrock K, Plaks V, Werb Z . (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52–67.
Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J et al. (2007). Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 67: 8229–8239.
Kwei KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, Salari K et al. (2008). Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27: 3635–3640.
Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P et al. (2007). Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 67: 8504–8510.
Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811–816.
Mareel M, Leroy A . (2003). Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83: 337–376.
Marfella CG, Imbalzano AN . (2007). The Chd family of chromatin remodelers. Mutat Res 618: 30–40.
Mason SD, Joyce JA . (2011). Proteolytic networks in cancer. Trends Cell Biol 21: 228–237.
Menon T, Yates JA, Bochar DA . (2010). Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8. Mol Endocrinol 24: 1165–1174.
Nagarajan P, Onami TM, Rajagopalan S, Kania S, Donnell R, Venkatachalam S . (2009). Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene 28: 1053–1062.
Olshen AB, Venkatraman ES, Lucito R, Wigler M . (2004). Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5: 557–572.
Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S et al. (2011). Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 21: 47–55.
Shen MM, Abate-Shen C . (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24: 1967–2000.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11–22.
Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P et al. (2011). Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539–542.
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T et al. (2010). ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532–1543.
Acknowledgements
We wish to thank the members of the Pollack lab for helpful discussion. Supported by grants from the NIH (CA122246 to JRP; CA111782 to JDB; CA130472 to SH), the Burroughs Wellcome Fund (1007519 to JRP), the American Cancer Society (PF-08-078-01-MGO to SH), Prostate Cancer Canada (to JL) and the Stanford Cancer Center (to JRP).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Huang, S., Gulzar, Z., Salari, K. et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 31, 4164–4170 (2012). https://doi.org/10.1038/onc.2011.590
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.590
Keywords
This article is cited by
-
Diversity roles of CHD1L in normal cell function and tumorigenesis
Biomarker Research (2021)
-
Chd1 protects genome integrity at promoters to sustain hypertranscription in embryonic stem cells
Nature Communications (2021)
-
Resistance to the Androgen Receptor Centred Therapies: Biology and Management
SN Comprehensive Clinical Medicine (2021)
-
The chromatin remodeler Chd1 regulates cohesin in budding yeast and humans
Scientific Reports (2019)
-
Molecular Subtypes of Prostate Cancer
Current Oncology Reports (2018)